APO Research
Talk to an analyst

APO RESEARCH · REPORT

Blood Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Blood Cancer Drugs Market Outlook and Growth Opportunities 2026

30 December 2025198 pages

Choose your research edition.

Industry ResearchBlood Cancer Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Blood Cancer Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Blood Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Blood Cancer Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Blood Cancer Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Blood Cancer Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Blood Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Blood Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Blood Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Blood Cancer Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Blood Cancer Drugs market include Astellas Pharma,, AstraZeneca PLC,, Bayer AG,, Bristol-Myers Squibb Company,, Celgene Corporation,, F.Hoffmann-La Roche,, AbbVie, Amgen, and Pfizer,, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Blood Cancer Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Blood Cancer Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Blood Cancer Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Blood Cancer Drugs market.

Blood Cancer Drugs Segment by Company

Astellas Pharma,

AstraZeneca PLC,

Bayer AG,

Bristol-Myers Squibb Company,

Celgene Corporation,

F.Hoffmann-La Roche,

AbbVie

Amgen,

Pfizer,

Eli Lilly,

Novartis

Johnson & Johnson,

Takeda Pharmaceutical Company Ltd,

Blood Cancer Drugs Segment by Type

Blood Chemotherapy Drugs

Blood Targeted Therapy Drugs

Blood Cancer Drugs Segment by Application

lymphoma

Multiple Myeloma

Leukemia

Blood Cancer Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Blood Cancer Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Blood Cancer Drugs key companies, revenue, market share, and recent developments.

3. To split the Blood Cancer Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Blood Cancer Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Blood Cancer Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Blood Cancer Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Blood Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Blood Cancer Drugs industry.

Chapter 3: Detailed analysis of Blood Cancer Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Blood Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Blood Cancer Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Blood Cancer Drugs Industry Trends Table 2. Blood Cancer Drugs Industry Drivers Table 3. Blood Cancer Drugs Industry Opportunities and Challenges Table 4. Blood Cancer Drugs Industry Restraints Table 5. Global Blood Cancer Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Blood Cancer Drugs Revenue Share by Company (2021-2026) Table 7. Global Blood Cancer Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Blood Cancer Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Blood Cancer Drugs Company, Product Type & Application Table 10. Global Blood Cancer Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Blood Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Blood Chemotherapy Drugs Table 15. Significant Companies of Blood Targeted Therapy Drugs Table 16. Global Blood Cancer Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Blood Cancer Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Blood Cancer Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Blood Cancer Drugs Sales Value Share by Type (2021-2026) Table 20. Global Blood Cancer Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of lymphoma Table 22. Significant Companies of Multiple Myeloma Table 23. Significant Companies of Leukemia Table 24. Global Blood Cancer Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Blood Cancer Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Blood Cancer Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Blood Cancer Drugs Sales Value Share by Application (2021-2026) Table 28. Global Blood Cancer Drugs Sales Value Share by Application (2027-2032) Table 29. Global Blood Cancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Blood Cancer Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Blood Cancer Drugs Sales Value Share by Region (2021-2026) Table 32. Global Blood Cancer Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Blood Cancer Drugs Sales Value Share by Region (2027-2032) Table 34. Global Blood Cancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Blood Cancer Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Blood Cancer Drugs Sales Value Market Share by Country (2021-2026) Table 37. Global Blood Cancer Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Blood Cancer Drugs Sales Value Market Share by Country (2027-2032) Table 39. Astellas Pharma, Company Information Table 40. Astellas Pharma, Business Overview Table 41. Astellas Pharma, Blood Cancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Astellas Pharma, Blood Cancer Drugs Product Portfolio Table 43. Astellas Pharma, Recent Development Table 44. AstraZeneca PLC, Company Information Table 45. AstraZeneca PLC, Business Overview Table 46. AstraZeneca PLC, Blood Cancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. AstraZeneca PLC, Blood Cancer Drugs Product Portfolio Table 48. AstraZeneca PLC, Recent Development Table 49. Bayer AG, Company Information Table 50. Bayer AG, Business Overview Table 51. Bayer AG, Blood Cancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Bayer AG, Blood Cancer Drugs Product Portfolio Table 53. Bayer AG, Recent Development Table 54. Bristol-Myers Squibb Company, Company Information Table 55. Bristol-Myers Squibb Company, Business Overview Table 56. Bristol-Myers Squibb Company, Blood Cancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Bristol-Myers Squibb Company, Blood Cancer Drugs Product Portfolio Table 58. Bristol-Myers Squibb Company, Recent Development Table 59. Celgene Corporation, Company Information Table 60. Celgene Corporation, Business Overview Table 61. Celgene Corporation, Blood Cancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Celgene Corporation, Blood Cancer Drugs Product Portfolio Table 63. Celgene Corporation, Recent Development Table 64. F.Hoffmann-La Roche, Company Information Table 65. F.Hoffmann-La Roche, Business Overview Table 66. F.Hoffmann-La Roche, Blood Cancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. F.Hoffmann-La Roche, Blood Cancer Drugs Product Portfolio Table 68. F.Hoffmann-La Roche, Recent Development Table 69. AbbVie Company Information Table 70. AbbVie Business Overview Table 71. AbbVie Blood Cancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. AbbVie Blood Cancer Drugs Product Portfolio Table 73. AbbVie Recent Development Table 74. Amgen, Company Information Table 75. Amgen, Business Overview Table 76. Amgen, Blood Cancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Amgen, Blood Cancer Drugs Product Portfolio Table 78. Amgen, Recent Development Table 79. Pfizer, Company Information Table 80. Pfizer, Business Overview Table 81. Pfizer, Blood Cancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer, Blood Cancer Drugs Product Portfolio Table 83. Pfizer, Recent Development Table 84. Eli Lilly, Company Information Table 85. Eli Lilly, Business Overview Table 86. Eli Lilly, Blood Cancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Eli Lilly, Blood Cancer Drugs Product Portfolio Table 88. Eli Lilly, Recent Development Table 89. Novartis Company Information Table 90. Novartis Business Overview Table 91. Novartis Blood Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Novartis Blood Cancer Drugs Product Portfolio Table 93. Novartis Recent Development Table 94. Johnson & Johnson, Company Information Table 95. Johnson & Johnson, Business Overview Table 96. Johnson & Johnson, Blood Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Johnson & Johnson, Blood Cancer Drugs Product Portfolio Table 98. Johnson & Johnson, Recent Development Table 99. Takeda Pharmaceutical Company Ltd, Company Information Table 100. Takeda Pharmaceutical Company Ltd, Business Overview Table 101. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product Portfolio Table 103. Takeda Pharmaceutical Company Ltd, Recent Development Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Blood Cancer Drugs Product Image Figure 2. Global Blood Cancer Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Blood Cancer Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Blood Cancer Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Blood Chemotherapy Drugs Image Figure 8. Blood Targeted Therapy Drugs Image Figure 9. Global Blood Cancer Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Blood Cancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Blood Cancer Drugs Sales Value Share by Type (2021-2032) Figure 12. lymphoma Image Figure 13. Multiple Myeloma Image Figure 14. Leukemia Image Figure 15. Global Blood Cancer Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Blood Cancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Blood Cancer Drugs Sales Value Share by Application (2021-2032) Figure 18. Global Blood Cancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Blood Cancer Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Blood Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 21. North America Blood Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Blood Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Blood Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Blood Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Blood Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Blood Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. South America Blood Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Blood Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Blood Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Blood Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Blood Chemotherapy Drugs
  • Blood Targeted Therapy Drugs
Applications
  • lymphoma
  • Multiple Myeloma
  • Leukemia
Companies covered
  • Astellas Pharma,
  • AstraZeneca PLC,
  • Bayer AG,
  • Bristol-Myers Squibb Company,
  • Celgene Corporation,
  • F.Hoffmann-La Roche,
  • AbbVie
  • Amgen,
  • Pfizer,
  • Eli Lilly,
  • Novartis
  • Johnson & Johnson,
  • Takeda Pharmaceutical Company Ltd,

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Blood Cancer Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Blood Cancer Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Blood Cancer Drugs Market Dynamics
  1. 2.1 Blood Cancer Drugs Industry Trends
  2. 2.2 Blood Cancer Drugs Industry Drivers
  3. 2.3 Blood Cancer Drugs Industry Opportunities and Challenges
  4. 2.4 Blood Cancer Drugs Industry Restraints
3 Blood Cancer Drugs Market by Company
  1. 3.1 Global Blood Cancer Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Blood Cancer Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Blood Cancer Drugs Company Ranking (2024-2026)
  4. 3.4 Global Blood Cancer Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Blood Cancer Drugs Company Product Type and Application
  6. 3.6 Global Blood Cancer Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Blood Cancer Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Blood Cancer Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Blood Cancer Drugs Market by Type
  1. 4.1 Blood Cancer Drugs Type Introduction
  2. 4.1.1 Blood Chemotherapy Drugs
  3. 4.1.2 Blood Targeted Therapy Drugs
  4. 4.2 Global Blood Cancer Drugs Sales Value by Type
  5. 4.2.1 Global Blood Cancer Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Blood Cancer Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Blood Cancer Drugs Sales Value Share by Type (2021-2032)
5 Blood Cancer Drugs Market by Application
  1. 5.1 Blood Cancer Drugs Application Introduction
  2. 5.1.1 lymphoma
  3. 5.1.2 Multiple Myeloma
  4. 5.1.3 Leukemia
  5. 5.2 Global Blood Cancer Drugs Sales Value by Application
  6. 5.2.1 Global Blood Cancer Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Blood Cancer Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Blood Cancer Drugs Sales Value Share by Application (2021-2032)
6 Blood Cancer Drugs Regional Value Analysis
  1. 6.1 Global Blood Cancer Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Blood Cancer Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Blood Cancer Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Blood Cancer Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Blood Cancer Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Blood Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Blood Cancer Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Blood Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Blood Cancer Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Blood Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Blood Cancer Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Blood Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Blood Cancer Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Blood Cancer Drugs Sales Value Share by Country, 2025 VS 2032
7 Blood Cancer Drugs Country-level Value Analysis
  1. 7.1 Global Blood Cancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Blood Cancer Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Blood Cancer Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Blood Cancer Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Blood Cancer Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Blood Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Blood Cancer Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas Pharma,
  2. 8.1.1 Astellas Pharma, Company Information
  3. 8.1.2 Astellas Pharma, Business Overview
  4. 8.1.3 Astellas Pharma, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Pharma, Blood Cancer Drugs Product Portfolio
  6. 8.1.5 Astellas Pharma, Recent Developments
  7. 8.2 AstraZeneca PLC,
  8. 8.2.1 AstraZeneca PLC, Company Information
  9. 8.2.2 AstraZeneca PLC, Business Overview
  10. 8.2.3 AstraZeneca PLC, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca PLC, Blood Cancer Drugs Product Portfolio
  12. 8.2.5 AstraZeneca PLC, Recent Developments
  13. 8.3 Bayer AG,
  14. 8.3.1 Bayer AG, Company Information
  15. 8.3.2 Bayer AG, Business Overview
  16. 8.3.3 Bayer AG, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer AG, Blood Cancer Drugs Product Portfolio
  18. 8.3.5 Bayer AG, Recent Developments
  19. 8.4 Bristol-Myers Squibb Company,
  20. 8.4.1 Bristol-Myers Squibb Company, Company Information
  21. 8.4.2 Bristol-Myers Squibb Company, Business Overview
  22. 8.4.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Company, Blood Cancer Drugs Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Company, Recent Developments
  25. 8.5 Celgene Corporation,
  26. 8.5.1 Celgene Corporation, Company Information
  27. 8.5.2 Celgene Corporation, Business Overview
  28. 8.5.3 Celgene Corporation, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Celgene Corporation, Blood Cancer Drugs Product Portfolio
  30. 8.5.5 Celgene Corporation, Recent Developments
  31. 8.6 F.Hoffmann-La Roche,
  32. 8.6.1 F.Hoffmann-La Roche, Company Information
  33. 8.6.2 F.Hoffmann-La Roche, Business Overview
  34. 8.6.3 F.Hoffmann-La Roche, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 F.Hoffmann-La Roche, Blood Cancer Drugs Product Portfolio
  36. 8.6.5 F.Hoffmann-La Roche, Recent Developments
  37. 8.7 AbbVie
  38. 8.7.1 AbbVie Company Information
  39. 8.7.2 AbbVie Business Overview
  40. 8.7.3 AbbVie Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Blood Cancer Drugs Product Portfolio
  42. 8.7.5 AbbVie Recent Developments
  43. 8.8 Amgen,
  44. 8.8.1 Amgen, Company Information
  45. 8.8.2 Amgen, Business Overview
  46. 8.8.3 Amgen, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amgen, Blood Cancer Drugs Product Portfolio
  48. 8.8.5 Amgen, Recent Developments
  49. 8.9 Pfizer,
  50. 8.9.1 Pfizer, Company Information
  51. 8.9.2 Pfizer, Business Overview
  52. 8.9.3 Pfizer, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer, Blood Cancer Drugs Product Portfolio
  54. 8.9.5 Pfizer, Recent Developments
  55. 8.10 Eli Lilly,
  56. 8.10.1 Eli Lilly, Company Information
  57. 8.10.2 Eli Lilly, Business Overview
  58. 8.10.3 Eli Lilly, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly, Blood Cancer Drugs Product Portfolio
  60. 8.10.5 Eli Lilly, Recent Developments
  61. 8.11 Novartis
  62. 8.11.1 Novartis Company Information
  63. 8.11.2 Novartis Business Overview
  64. 8.11.3 Novartis Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novartis Blood Cancer Drugs Product Portfolio
  66. 8.11.5 Novartis Recent Developments
  67. 8.12 Johnson & Johnson,
  68. 8.12.1 Johnson & Johnson, Company Information
  69. 8.12.2 Johnson & Johnson, Business Overview
  70. 8.12.3 Johnson & Johnson, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Johnson & Johnson, Blood Cancer Drugs Product Portfolio
  72. 8.12.5 Johnson & Johnson, Recent Developments
  73. 8.13 Takeda Pharmaceutical Company Ltd,
  74. 8.13.1 Takeda Pharmaceutical Company Ltd, Company Information
  75. 8.13.2 Takeda Pharmaceutical Company Ltd, Business Overview
  76. 8.13.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product Portfolio
  78. 8.13.5 Takeda Pharmaceutical Company Ltd, Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst